Company intelligence / Profile preview

Chengdu MFS Pharma

Chengdu, Sichuan, China

Ownership: Private
Development stage: Other

Overview

Chengdu MFS Pharma is a clinical-stage biopharmaceutical company headquartered in Chengdu, China, dedicated to the discovery and development of innovative small molecule drugs. The company primarily focuses on metabolic diseases, such as type 2 diabetes and non-alcoholic steatohepatitis (NASH), as well as oncology. Its lead program, MFS-1517, is a potent GPR120 agonist designed to address insulin resistance and chronic inflammation. By leveraging its internal medicinal chemistry expertise, MFS Pharma aims to provide high-quality, differentiated therapeutic solutions for patients with high unmet medical needs.

Therapeutic areas: OncologyMetabolic DisordersEndocrinologyGastroenterology
Modalities: Small molecule
Industry: Biotech

Drug pipeline

1 asset

MFS-16

Unknown

Beyond the preview

Go deeper on Chengdu MFS Pharma.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Chengdu MFS Pharma.

Explore the full profile